LabGenius is a biopharmaceutical company developing next generation protein therapeutics using a machine learning-driven evolution engine (EVA™). They integrate technologies from machine learning, synthetic biology, and robotics for protein engineering.

LabGenius was founded by James Field.

The CEO of LabGenius is James Field. You can find more information about them on their LinkedIn profile.

LabGenius has raised a total of $$28 Million across 2 funding rounds. The most recent funding was completed on 2024-06-21.

LabGenius's key investors include M Ventures, Innovate UK.

LabGenius is headquartered in London, United Kingdom.

LabGenius was founded in 2012.

LabGenius has 51-100 employees.

You can visit LabGenius's official website at http://www.labgeni.us.

LabGenius's latest funding round was a Series B round of $$44.5 Million completed on 2024-06-21.

James Field

LabGenius develops next generation protein therapeutics using a machine learning-driven evolution engine (EVA™).

$28 Million

2024-06-21

M Ventures Innovate UK

Competition in the biotechnology sector Maintaining funding for expansion

Collaboration with pharmaceutical companies Expanding the application of AI in drug discovery

LabGenius has secured £35 million ($44.5 million) in a Series B raise to expand its antibody discovery platform and advance a pipeline of cancer candidates. LabGenius has already raised $28 million in funding and is starting to collaborate with pharmaceutical companies.